Affordable Access

[HCV protease inhibitors and drug resistance].

Authors
Type
Published Article
Journal
Przegla̧d epidemiologiczny
Publication Date
Volume
66
Issue
1
Pages
55–57
Identifiers
PMID: 22708299
Source
Medline
License
Unknown

Abstract

Treatment efficacy ofDAAs is limited in the presence of HCV mutants which revealed amino-acids substitution and drug resistance. Because of the high genetic heterogeneity of HCV and its rapid replication, monotherapy with DAA agents poses a high risk for selection of resistant variants. We review the factors that determine resistance, the methods of resistance detection and strategies to avoid the selection of resistant variants.

Statistics

Seen <100 times